Medtech ups and downs of Scottish CHD (coronary heart disease) campaign
This article was originally published in Clinica
Scotland has reported a significant rise in the number of revascularisations over the last year, coupled with a fall in the number of new diagnoses of coronary heart disease (CHD) and related deaths. However, with much room to improve in what has made Scotland reputedly the world's worst region for this type of condition, these areas remain its greatest healthcare priority.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.